Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Tue, 26th Oct 2021 19:06

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Yellow Cake PLC - Jersey-based investor in uranium - Plans to raise USD150 million through placing. Will fund purchase of three millions pounds of physical uranium. "The long term outlook for the uranium price remains strong, driven by the more positive demand outlook and on-going supply constraints, causing the supply deficit to grow every year. We continue to seek further opportunities for value accretive opportunistic uranium purchases at an attractive price," Chief Executive Officer Andre Liebenberg says.

----------

Mercia Asset Management PLC - West Midlands-based asset manager - Completes GBP1.8 million investment into new portfolio company Forensic Analytics Ltd, alongside GBP2.7 million backing by Mercia managed Northern VCTs. "Following this investment, Mercia holds an 8.9% fully diluted direct equity stake in Forensic Analytics, with the Northern VCTs holding a further 13.9% fully diluted equity stake," Mercia says.

----------

Tern PLC - investor focused on the internet of things - Says "significant business momentum" continues across principal portfolio firms. Device Authority Ltd investee launches KeyScaler Edge offering to address IoT security challenges. "In addition to new customer wins and repeat orders, Device Authority have recently entered into further distribution partnerships, including with Trusted Objects, a leading independent player in cybersecurity technologies for embedded systems and cloud device management platforms, and with Titan Automotive Solutions, a leading provider of car connectivity solutions with a global presence," Tern says. Tern owns 57% of Device Authority. Virtual reality focused investee FVRVS Ltd, meanwhile, wins deal with company previously using a competitor's product. InVMA Ltd sees "strong sales growth", while Wyld Networks AB "continued to make further significant progress following its IPO on the NASDAQ First North Growth Market in Stockholm".

----------

Path Investments PLC - Bingley, England-based natural resources investment company - Says longstop date for DG Innovate Ltd buy extended to December 31. "Path and its advisers continue to progress the proposed transaction," company says.

----------

Caerus Mineral Resources PLC - London-based exploration & resource development company - Says trenching of stockpiles at Troulli project finds "very high-grade visible copper mineralisation". Copper grades are "highly significant", based on semi-quantitative XRF analysis. "Samples have been collected and are ready for dispatch to the assay laboratory," Caerus says. Duplicate samples also sent to partner Jubilee Metals Group PLC for testwork.

----------

Petra Diamonds Ltd - London-based diamond miner - Says revenue in first quarter ended September 30 improves year-on-year to USD114.9 million from USD77.7 million a year earlier. Says output falls annually to 861,991 carats from 974,346 carats.

----------

IMC Exploration Group PLC - Dublin-based exploration company focused on Ireland - Says drillhole 21-3850-01 at West Avoca encounters "four zones of massive and semi massive sulphide mineralisation". Says 18.7 metre interval or zinc, lead and silver mineralisation found. "IMC plans that the drill programme will allow an independent resource calculation to be undertaken in addition to that already in place for the spoils' and tailings' project," IMC adds.

----------

Angus Energy PLC - oil & gas development company - Shares revised competent persons report at Saltfleetby gas field. Says conservative estimate, or P90, of future cashflows to Angus stands at GBP31.7 million. Mid-case, or P50, has it at GBP55.9 million. Angus adds: "In summary the report estimates production giving rise to gross field revenues, before costs on a mid-case basis of GBP230 million (previously GBP141 million) of which Angus's share is 51%."

----------

Oxford Metrics PLC - software company servicing infrastructure, life sciences, entertainment and engineering markets - Says motion measurement unit Vicon wins deal with volumetric content and virtual production firm Dimension Studios. "Vicon's tracking, of both rigid and full body subjects, will be used alongside Dimension Studio's volumetric and real-time development capabilities by leading visual effects company DNEG for several high-profile virtual production projects - including a major motion picture and a 10-hour TV series," Oxford Metrics says.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says third quarter sales "strong" at USD964,000. "Importantly, both the September and June 2021 quarters combined have delivered a record USD2.24 million in cash receipts from customers over the 6-month period, with increasing month on month sales generated from new key markets, such as the UK and Ireland," MGC adds.

----------

ReNeuron Group PLC - Bridgend, Wales-based exosome therapeutics company - Teams with University College London to research generation of immune cells from induced pluripotent stem cells as a potential cancer therapy. ReNeuron will provide UCL with the stem cells. Company adds: "Induced pluripotent stem cells can differentiate into any cell type found in the body, but unlike most iPSCs, ReNeuron's proprietary CTX-iPSCs carry the conditional immortalisation system incorporated into CTX. ReNeuron's CTX derived iPSC's are available as clinical grade material potentially allowing faster development of arising therapeutics and the company believes that its conditional immortalisation technology could allow the company to manufacture cost efficiently at scale to treat large numbers of patients providing 'off the shelf' cell therapies."

----------

Omni Egis PLC - debt financing solutions provider for small to medium-sized businesses - Says AQSE listing "not commercial for the company to raise funds at the current share price". Notes market capitalisation currently below liquid resources. Convenes general meeting on November 18 to vote on AQSE withdrawal.

----------

CATCo Reinsurance Opportunities Fund Ltd - invests in catastrophe reinsurance risks - Receives "substantial level of investor support" for Markel CATCo Investment Management Ltd-funded buyout. Markel is CATCo's manager.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
11 Mar 2013 08:31

ReNeuron Group wins grants for stem cell therapy development

ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy. The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council. The first award of £0.4m will be used for

Read more
29 Jan 2013 10:29

ReNeuron Group edges further in stem cell therapy research for stroke patients

ReNeuron Group received the green light to complete the final stages of first phase safety testing of its ReN001 stem cell therapy for disabled stroke patients in Scotland, the company announced Tuesday. The ReN001 stem cell therapy was being administered in ascending doses to a total of 12 stroke

Read more
5 Nov 2012 08:33

Angel Biotech signs new contract with ReNeuron

Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year. The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients. ReNeuron's ReN001

Read more
17 Oct 2012 07:27

ReNeuron progresses stroke clinical trial

ReNeuron has reported further progress in the clinical trial of its ReN001 stem cell therapy for disabled stroke patients, known as the PISCES study. The third and penultimate batch of three patients have all been successfully treated with ReN001 and discharged from hospital with no acute safety is

Read more
11 Sep 2012 14:25

Small caps round-up: ReNeuron, Havelock, Goodwin

Clinical-stage stem cell group ReNeuron has achieved further significant milestones with its ReN001 and ReN009 programmes in stroke and critical limb ischaemia, with the filing of two further clinical trial applications to progress the clinical development of these novel therapies. Michael Hunt, Chi

Read more
14 Aug 2012 12:35

Small caps round-up: ReNeuron, Eckoh, Healthcare Locums

Clinical-stage stem cell group ReNeuron surged on Tuesday after saying that the Data Safety Monitoring Board gave a favourable recommendation to proceed to the with a higher dose of its ReN001 stem cell therapy in a clinical trial. 'This represents a further important milestone for the study as we m

Read more
28 Jun 2012 14:22

ReNeuron's full-year results disappoint

ReNeuron Group, a UK-based stem cell company, suffered a decline in its share price on Thursday after posting an increase in pre-tax losses for the year ended March 31st. Loss before tax widened from £6.64m to £6.8m year-on-year (y/y), while revenues rose from £0.029m to £0.04m, representing royal

Read more
16 May 2012 15:18

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and impleme

Read more
27 Apr 2012 14:20

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Read more
3 Apr 2012 12:39

Small caps round-up: DQ Entertainment, Tristel, ReNeuron

DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the seco

Read more
11 Jan 2012 10:55

ReNeuron down despite positive data release

In its second announcement of the year, ReNeuron, the Surrey based stem cell developer, has announced new data on the stability of the company's CTX stem cell line. Researchers from University College London are due to tell a conference in San Diego that the results show "CTX cells retained their m

Read more
3 Jan 2012 08:19

ReNeuron announces positive data

Stem cells therapy developer ReNeuron has gained positive data from a recent pre-clinical study which used its ReN001 stem cell therapy for disabled stroke patients. The newly-published data show significantly improved outcomes in the key behavioural tests in the cell-treated group. A gradual im

Read more
13 Sep 2011 15:09

ReNeuron successfully treats first patient

Stem cells therapy developer ReNeuron has successfully treated a stroke patient who underwent the safe, first-time administration of a higher dose of its new drug, ReN001. The firm ran the increased level of the stem cell therapy drug after the independent Data Safety Monitoring Board recommended t

Read more
13 Dec 2010 18:06

ReNeuron cash call will last two years

Stem cell therapies developer ReNeuron is raising £10m from a share issue at 5.5p a share. The cash will finance the pre-clinical and clinical development costs of the main drug programmes, as well as general running costs, for the next two years. The cash will also be used to complete manufacturi

Read more
12 Jul 2010 08:31

Small caps round-up: Ariana Resources, Michelmersh, ReNeuron...

Shares in Ariana Resources rallied after the Turkey-focused gold miner announces the completion of its joint venture agreement with Proccea to develop the Red Rabbit Project in western Turkey. The group said results from the recent resource drilling programme are expected shortly. Managing directo

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.